Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe
- Under the terms of this MOU, Awakn will explore a data licensing agreement with MAPS to support Awakn's Phase IIb and planned Phase III studies for MDMA-assisted therapy for AUD in Europe.
- Awakn and MAPS will also assess a partnership to secure marketing authorisation/regulatory approval for the ethical commercialization of MDMA-assisted therapy for the treatment of AUD in Europe.
- "We're delighted to be entering into this MoU with AWAKN which holds great promise for people suffering from AUD."
- About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction.